信息搜索
信息关键字：药
  

共有5246条记录

分页[首页] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263]

·立方制药：两位董事、高管拟分别减持不超0.18%公司股份2022-9-15 15:16:26
·以岭医药等被恢复执行1300万2022-9-15 14:17:16
·立方制药两高管宣布减持：原因自身资金需求2022-9-15 14:01:25
·中成药集采将导致行业洗牌机构称行业长期需求持续向好2022-9-15 12:27:24
·宏源药业IPO：销售费用披露矛盾重重审计机构“独立性”遭质疑2022-9-15 11:35:07
·恒瑞医药推1.3折员工持股迎创新挑战孙飘扬复出转型承压净利近18年首降2022-9-15 11:18:53
·恒生医药ETF盘中涨超2%，药明生物强势反弹2022-9-15 10:57:09
·双鹭药业9月14日主力资金净卖出4494.60万元2022-9-15 10:04:19
·“花无百日红”，红利过后的以岭药业恐难寻增长点2022-9-15 9:59:47
·【早盘内参】工信部：将加快推进医药工业创新成果产业化2022-9-15 5:07:56
·体制改革激荡医药生物产业上市公司担起创新发展大任2022-9-15 1:46:26
·金鸿药业拟向金融机构申请综合授信综合授信额度不超过4000万2022-9-14 22:03:49
·金鸿药业收到国家药品监督管理局核准签发的化学原料药上市申请批准通知书2022-9-14 21:58:51
·双成药业：双成投资所持2150万股被质押占公司总股本比例5.18%2022-9-14 19:42:37
·莱美药业：注射用磷酸氟达拉滨通过仿制药一致性评价2022-9-14 19:15:27
·中红医疗：与上药控股签订战略合作协议2022-9-14 19:07:56
·白云山：分公司药品头孢丙烯颗粒通过仿制药一致性评价2022-9-14 18:16:33
·中成药国家集采来了！首次涉及复方血栓通、冠心宁、华蟾素等16种药品2022-9-14 17:30:11
·华润双鹤：华氧氟沙星氯化钠注射液通过仿制药质量和疗效一致性评价2022-9-14 17:05:31
·百元股数量达165只电子、电力设备、医药生物行业占比均超10%2022-9-14 17:02:13

分页[首页] [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263]